rationale for combining acalabrutinib with bendamustine and rituximab in mcl
Published 5 years ago • 208 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
1:31
acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or r/r mcl
-
1:51
safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in mcl
-
1:37
bendamustine/rituximab as induction therapy in mcl
-
1:07
dr. wang on addition of acalabrutinib to bendamustine/rituximab in mcl
-
0:46
dr. goy discusses potential for combination therapy in mcl
-
1:50
acalabrutinib and rituximab as first-line therapy for older patients with mcl
-
1:06
dr. phillips on the safety of acalabrutinib plus bendamustine/rituximab in mcl
-
6:30
fl: switching to bendamustine/rituximab at progression
-
0:56
promising results for bendamustine/rituximab plus polatuzumab vedotin in lymphomas
-
3:19
fda-approved agents for the treatment of mcl
-
1:35
dr. patel on induction therapy with bendamustine and rituximab in mcl
-
3:42
acalabrutinib plus venetoclax and rituximab in mcl & the importance of chemotherapy-free regimens
-
5:28
first results of a prospective bendamustine/rituximab trial in patients with mcl
-
0:34
rationale for genetic testing in patients with dlbcl
-
0:58
recent advancements in mantle cell lymphoma
-
1:27
acalabrutinib in combination with umbralisib and ublituximab in previously untreated mcl
-
0:26
acalabrutinib plus venetoclax and rituximab in the treatment of mcl
-
5:36
achieving complete remission of mcl
-
5:12
phase ii trial of acalabrutinib, lenalidomide and rituximab in patients with mcl